FDA approval for adalimumab biosimilar Idacio
Fresenius Kabi, a global health care company that specializes in pharmaceuticals, medical technologies, and nutrition products for critical and chronic conditions, announced that the FDA has approved its citrate-free adalimumab biosimilar Idacio for use in the treatment of chronic autoimmune diseases for all eligible indications of the reference product, Humira(adalimumab)
Since its first launch in 2019, Idacio has been approved and commercialized in over 37 countries around the world. Fresenius Kabi plans to launch the product in the U.S., in a self-administered prefilled syringe and a self-administered pre-filled pen (autoinjector) starting from July 2023.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins